Industry News

Warning Letter Sent to Private Label Skin Care, Inc.

FDA cites company's failure to establish an adequate quality control unit.

Author Image

By: Christine Esposito

Editor-in-Chief

The US FDA has sent a warning letter to Private Label Skin Care, Inc., Canoga Park, CA. FDA conducted an inspection from June 16-23, 2025 where it found significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. In the Dec. 18, 2025 letter, FDA said the firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process material...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters